The announcement of a Virtual R&D Day suggests Apogee Therapeutics is making significant progress in its pipeline, which could attract investor interest and positively impact the stock price. The focus on reshaping the standard of care in I&I with best-in-class treatments indicates potential for future growth and innovation.